Navigation Links
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement
Date:11/8/2010

ed in 4.9 percent of patients; 6.9 percent of patients experienced at least one infusion reaction.  

About Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory condition that is often characterized by symptoms that include pain, stiffness and inflammation, and in some cases, joint destruction and disability. The Arthritis Foundation estimates that approximately 1.3 million people in the United States are living with RA, the majority of whom are women.  For more information visit the Arthritis Foundation.

About REMICADE

REMICADE was the first anti-TNF-alpha treatment to be approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in clinical trials over the past 17 years and through commercial experience with more than one million patients treated worldwide.

In the U.S., REMICADE is approved for the following indications:

  • Reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA, when administered in combination with methotrexate.  
  • Reducing signs and symptoms in patients with active AS.
  • Reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active CD who have had an inadequate response to conventional therapy.  
  • Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients wit
    '/>"/>

SOURCE Centocor Ortho Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
2. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
3. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
4. New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
5. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
11. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 Global ENT ... to reach USD 23.01 million in 2022, according to ... base of geriatric population, increasing prevalence of ear, nose, ... of awareness among target customer base are expected serve ... forecast period. According to estimates published by the WHO, ...
(Date:7/30/2015)... LAGUNA HILLS, Calif. , July 30, 2015 ... developing nanoparticle drug delivery platforms, has received Orphan ... (FDA) for a second drug product that uses ... is a formulation of dactinomycin for the treatment ... bone cancer. The FDA granted NanoSmart,s Orphan Drug ...
(Date:7/30/2015)... -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on ... financial results and provide a corporate update. Arena will ... Market closes that day. The conference call ... and 914.495.8552 for international callers. Please specify to the ...
Breaking Medicine Technology:ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 2Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 3Arena Pharmaceuticals to Host Second Quarter 2015 Financial Results and Corporate Update Conference Call and Webcast on Wednesday, August 5 4
(Date:7/30/2015)... , ... July 30, 2015 ... ... a video, “Beachside Nursing Center,” to announce its position as one of ... Beachside's administrator and staff members support the CMS rating system, which monitors ...
(Date:7/30/2015)... ... July 30, 2015 , ... Zejax is a New ... Increases Training Capability , World renown body weight trainer, Paul Ziachik, announces ... that dramatically increases a person’s training capability. , The American College of Sports ...
(Date:7/30/2015)... ... 2015 , ... Boston Web Marketing is proud ... Partners is the platform for search marketing agencies to communicate with the Google ... to run successful search marketing campaigns. Google Partners also affords businesses the opportunity ...
(Date:7/30/2015)... ... 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers ... well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with ... from around the world. , “Like treatment of any other disease or condition, making ...
(Date:7/30/2015)... ... ... InventHelp, a leading inventor service company, announces that one of its ... to apply lotion or medication to a hard-to-reach area. This invention is patented. , ... to the back, and provides thorough coverage. The product would prevent the user from ...
Breaking Medicine News(10 mins):Health News:Beachside Nursing Center Releases New Video 2Health News:Zejax is a Revolutionary New Way of BodyWeight Training Without Weights 2Health News:Boston Web Marketing Attends Google Partners All-Stars Summit 2Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... 40 percent of new moms aren,t married, CDC reports ... of unmarried women having children has risen sharply in the ... officials. , In the United States, 40 percent of births ... to women in their 20s, not teenagers, according to a ...
... The beta-carotene in so-called "Golden Rice" converts to vitamin ... Medicine (www.bcm.edu) and Tufts University in an article that appears ... Clinical Nutrition . , Golden Rice was developed ... Foundation with the goal of creating rice that had beta-carotene ...
... Department Nurses for Role in Prestigious DesignationEMERYVILLE, Calif., ... of the nation,s largest providers of emergency department ... its client, Palomar Pomerado Health (PPH) system, has ... Center (ANCC). Only five percent of U.S. hospitals ...
... discussion about trade-offsSTANFORD, Calif., May 13 Americans ... involved in health care reform, according to new ... Longevity (SCL).The findings are the result of a ... and united the typically disconnected worlds of politics, ...
... Sharing Miracles, a 30-minute public affairs television program ... patients has expanded its reach across America, now airing ... The current episode features nine-time NBA all-star and Basketball ... year, the Sharing Miracles network has expanded ...
... ST. LOUIS, May 13 Express Scripts, Inc. (Nasdaq: ... Deutsche Bank 34th Annual Health Care Conference on May 19, ... Boston. This presentation will also be broadcast via the Internet ... Express Scripts web site at http://www.express-scripts.com . RealPlayer ...
Cached Medicine News:Health News:More Single Women Are Having Babies 2Health News:More Single Women Are Having Babies 3Health News:More Single Women Are Having Babies 4Health News:Palomar Pomerado Health System Achieves National Recognition for Nursing Excellence by the American Nurses Credentialing Center 2Health News:Palomar Pomerado Health System Achieves National Recognition for Nursing Excellence by the American Nurses Credentialing Center 3Health News:Stanford Center on Longevity Releases New Findings About Voter Attitudes on Health Care Reform 2Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 2Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 3Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 4Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 5Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 6Health News:'Sharing Miracles' Television Program Now Airs on More Than 300 Stations 7
Contoured design provides secure support and immobilization of the wrist and distal forearm while preserving finger mobility...
Designed to provide comfortable support, protection and immobilization MCP joint along with immobilization of the wrist...
Design allows for easy-one hand application to provide support and immobilization of the wrist while preserving finger mobility...
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
Medicine Products: